176 related articles for article (PubMed ID: 21889981)
1. Viral-mediated overexpression of mutant huntingtin to model HD in various species.
Ruiz M; Déglon N
Neurobiol Dis; 2012 Nov; 48(2):202-11. PubMed ID: 21889981
[TBL] [Abstract][Full Text] [Related]
2. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.
Huang B; Schiefer J; Sass C; Landwehrmeyer GB; Kosinski CM; Kochanek S
Hum Gene Ther; 2007 Apr; 18(4):303-11. PubMed ID: 17472569
[TBL] [Abstract][Full Text] [Related]
3. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
Franich NR; Fitzsimons HL; Fong DM; Klugmann M; During MJ; Young D
Mol Ther; 2008 May; 16(5):947-56. PubMed ID: 18388917
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
[TBL] [Abstract][Full Text] [Related]
5. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors.
Kirik D; Björklund A
Trends Neurosci; 2003 Jul; 26(7):386-92. PubMed ID: 12850435
[TBL] [Abstract][Full Text] [Related]
6. [Gene silencing approaches for the treatment of Huntington's disease].
Merienne N; Déglon N
Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease.
Cambon K; Déglon N
Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
[TBL] [Abstract][Full Text] [Related]
10. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease.
Zuleta A; Vidal RL; Armentano D; Parsons G; Hetz C
Biochem Biophys Res Commun; 2012 Apr; 420(3):558-63. PubMed ID: 22445760
[TBL] [Abstract][Full Text] [Related]
11. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
12. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
13. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
[TBL] [Abstract][Full Text] [Related]
14. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
15. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
Dufour BD; Smith CA; Clark RL; Walker TR; McBride JL
Mol Ther; 2014 Apr; 22(4):797-810. PubMed ID: 24390280
[TBL] [Abstract][Full Text] [Related]
16. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
[TBL] [Abstract][Full Text] [Related]
17. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
Wang LH; Qin ZH
Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
[TBL] [Abstract][Full Text] [Related]
18. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
[TBL] [Abstract][Full Text] [Related]
19. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
20. Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.
Pitzer M; Lueras J; Warden A; Weber S; McBride J
Brain Res; 2015 May; 1608():177-90. PubMed ID: 25732261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
